AbCellera Biologics (ABCL) Cash from Operations (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Cash from Operations came in at 33523000.0 in Q1 2026, down 190.14% YoY from 37189125.49 in Q1 2025, and up 3.51% on a QoQ basis from 34743000.0 in Q4 2025.
AbCellera Biologics (ABCL) Cash from Operations (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Cash from Operations data on file, last reported at 33523000.0 in Q1 2026.
- Quarterly Cash from Operations fell 190.14% year-over-year to 33523000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 153264000.0 (down 95.48% YoY) and the FY2025 annual result came in at 131295000.0, down 20.95% from the prior year.
- Cash from Operations advanced to 33523000.0 in Q1 2026, from 34743000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 273015000.0 in Q2 2022 to a low of 126786000.0 in Q3 2022.
- A 5-year average of 2346529.41 and a median of 28882000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 284.97% — and 2024, when it plunged 27147.17%.
- Tracing ABCL's Cash from Operations over 5 years: stood at 30912000.0 in 2022, then tumbled by 163.44% to 19611000.0 in 2023, then soared by 59.21% to 8000000.0 in 2024, then plunged by 334.29% to 34743000.0 in 2025, then advanced by 3.51% to 33523000.0 in 2026.
- The last three Cash from Operations figures came in at 33523000.0 (Q1 2026), 34743000.0 (Q4 2025), and 52594000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 25.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.92 Mn |
| Jun 30, 2026 | 25.92 Mn |
| Mar 31, 2026 | -33.52 Mn |
| Mar 31, 2026 | -33.52 Mn |
| Dec 31, 2025 | -34.74 Mn |
| Dec 31, 2025 | -34.74 Mn |
| Sep 30, 2025 | -52.59 Mn |
| Sep 30, 2025 | -52.59 Mn |
| Jun 30, 2025 | -32.40 Mn |
| Jun 30, 2025 | -32.40 Mn |
| Mar 31, 2025 | -11.55 Mn |
| Mar 31, 2025 | -11.55 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Sep 30, 2024 | -28.88 Mn |
| Sep 30, 2024 | -28.88 Mn |
| Jun 30, 2024 | -29.97 Mn |
| Jun 30, 2024 | -29.97 Mn |
| Mar 31, 2024 | -41.71 Mn |
| Mar 31, 2024 | -41.71 Mn |